Feed CORT
CO

Corcept Therapeutics

CORT · NASDAQ

$114.86 +1.69% (+$1.91)
1M -6.06%
Market Cap $12.4B
P/E Ratio 226.30x
Div. Yield -
ROE 8.37%

Bulios Fair Price

$68.81

40.1% downside

Preț actual

$114.86

Subevaluat Valoare justă Supraevaluat

Potrivit Bulios Fair Price, acțiunile CORT sunt în prezent supraevaluate față de prețul lor de piață. Cum funcționează?

Bulios Fair Price este o estimare a valorii corecte a unei acțiuni din modelul de evaluare Bulios. Este un punct de plecare pentru propria analiză, nu o recomandare de investiții. Cum funcționează?

Piotroski F-Score Moderate
6/9
Valuation
0 /100
Expensive
P/E 226.30x
EV/EBITDA 427.98x
P/FCF 116.19x
Growth
60 /100
Stable
EPS growth 1.95%
Rev. growth 23.74%
Book val. growth 8.88%
Profitability
54 /100
Moderate
Gross margin 98.30%
Net margin 6.61%
FCF margin 12.87%
Quality
34 /100
Average
ROIC 2.03%
ROE 8.37%
Asset turnover 0.93x
Debt
100 /100
Low
Debt/Equity 0.01x
Current ratio 2.86x
Net debt/EBITDA -3.53x
Stability
72 /100
Stable
Beta 0.45x
Rev. volatility 14.06%
Profitable years 6

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre CORT
Online

Despre companie

Corcept Therapeutics Incorporated (CORT) is an American biotechnology company specializing in research, development, and commercialization of drugs for the treatment of endocrine and psychiatric disorders. With activities in biotechnology and pharmacology, Corcept Therapeutics is a key player in the world of innovative treatment approaches. Their research focuses on discovering new treatment methods and therapies for patients with endocrine and psychiatric disorders, including Cushing's syndrome. The company aims to provide modern treatment solutions and improve the quality of life for patients. Corcept Therapeutics is characterized by expertise in pharmacology and endocrine medicine. Corcept Therapeutics Incorporated (CORT) shares could be suitable for investors looking for an investment opportunity in the biotechnology and pharmaceutical sector with a company that specializes in innovative treatment approaches and therapies for patients with endocrine and psychiatric disorders.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Medical - Pharmaceuticals

CEO

Joseph K. Belanoff

Employees

730

Headquarters

Redwood City

Evenimente viitoare

04 NOV.

Earnings

Upcoming earnings report

47d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.